However, the efficacy of SMO inhibitors in other solid carcinoma may not be as effective as in glioblastoma or base cell carcinoma due to activation of the non-canonical Hh signaling pathway or other oncogenic signaling pathways [15]. This evidence concerns the gene SMO and glioblastoma.